Application of danshinolic acid B in preparation of medicine of treating scleroderma

A technology of scleroderma and salvianolic acid, applied in skin diseases, drug combinations, antipyretics, etc., can solve problems such as difficulty in preventing disease progression, tissue damage, large side effects, and poor efficacy

Inactive Publication Date: 2015-04-29
FUDAN UNIV
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Once the disease develops to the stage of fibrosis, the existing treatment methods are difficult to prevent the progression of the disease and tissue damage
For scleroderma, Western medicine-based treatment measures are not effective or have relatively large side effects. So far, there are no scleroderma drugs approved by the US Food and Drug Administration (FDA) and my country's State Food and Drug Administration (SFDA)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of danshinolic acid B in preparation of medicine of treating scleroderma
  • Application of danshinolic acid B in preparation of medicine of treating scleroderma
  • Application of danshinolic acid B in preparation of medicine of treating scleroderma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] The compound salvianolic acid B used in the present invention is obtained through commercial channels.

[0051] Compound salvianolic acid B alleviates lung fibrosis in scleroderma mice:

[0052] Test objects: 7-week-old C57BL / 6 female mice, purchased from the Experimental Animal Center of Fudan University

[0053] experiment method:

[0054] 1) Establishment of scleroderma pulmonary fibrosis mouse model: Bleomycin-induced scleroderma mouse model is a mature and well-recognized tool for studying fibrosis by scientists from all over the world. Intubation of bleomycin into the lungs can cause pulmonary fibrosis. Seven-week-old C57BL / 6 female mice were used to establish a model of bleomycin (BLM)-induced pulmonary fibrosis in scleroderma by endotracheal intubation. The dosage of bleomycin was changed to 9mg / kg, given once. [Note: The mouse culture time is as described in 2)]

[0055] 2) The effect of compound SAB treatment on scleroderma fibrosis in mice: divided into ...

Embodiment 2

[0061] The compound salvianolic acid B inhibits the occurrence of TNFα-induced cellular inflammation:

[0062] Test objects: NIH3T3 cells (mouse embryonic fibroblasts), MRC5 cells (human embryonic lung fibroblasts) Test methods:

[0063] 1) Applying TNFα to stimulate cells to establish an in vitro inflammatory cell model (Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X, Zou H, Qiu J. Activation of Sirt1by resveratrol inhibits TNF-α induced inflammation in fibroblasts.PLoS One .2011;6(11):e27081), the expression levels of IL-1β, IL-6, COX-2, iNOS and other inflammatory factors at different time points of TNFα were detected by Real-time PCR;

[0064]2) Obtain cells from different treatment groups of SAB or TNFα. For SAB and TNFα treatment groups simultaneously, NIH3T3 cells were cultured with DMEM medium, MRC5 cells were cultured with MEM medium, and about 8*105 (10 of 5 After 24 hours of culture, add different concentrations of SAB into the cell culture medium (final concentration...

Embodiment 3

[0069] The compound salvianolic acid B exerts anti-fibrotic effects in fibroblasts:

[0070] Test objects: MRC5 cells (human embryonic lung fibroblasts), primary cultured skin fibroblasts from patients with scleroderma Test methods:

[0071] 1) The cell dynamics model analysis system based on xCELLIgence technology to study the effect of SAB on the proliferation of fibroblasts. Add 1000 cells to the wells of each E-Plates plate. After culturing for 24 hours, replace the culture medium without or containing 100ug / ml SAB into the cells, and observe the cell proliferation curve in real time. The larger the cell index, the more cells there are. [Description: The xCELLigence system is a non-labeled real-time cell analysis system launched by Roche, which uses bioelectrical resistance readings to non-subjectively quantify the cell state in real time. The system monitors cell activity in real time without adding labels. The system measures electrical impedance on interdigitated micr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of chemical engineering in a hospital, particularly relates to a new application of a small molecule compound, and further particularly relates to an application of a small molecule compound danshinolic acid B in preparation of a medicine of treating scleroderma. The invention provides an application of danshinolic acid B in preparation of a medicine of treating scleroderma, and further provides a corresponding medicine composition and a medicine preparation. The inventor of the invention makes an animal experiment, which shows that a compound SAB remarkably relieves the pulmonary fibrosis of a mice suffering from the scleroderma, and a further cell experiment indicates that the small molecule compound can inhibit cell inflammation induced by TNFalpha, and can inhibit the skin flbroblast of a patient suffering from the scleroderma cultured in vitro, human embryonic lung fibroblast proliferation and collagen expression, and inhibit transformation of pulmonary epithelial cells to mesenchymal cells. The application shows that the compound has a function of resisting fibrosis of the scleroderma, and has a good application prospect for preventing and treating the scleroderma.

Description

technical field [0001] The present invention relates to the field of hospital chemical industry, in particular to a new use of a small molecular compound, in particular to the use of the small molecular compound salvianolic acid B (also known as salvianolic acid B, salvianolic acid B) in the preparation of medicines for treating scleroderma use in . Background technique [0002] Scleroderma, also known as systemic sclerosis (SSc), is characterized by localized or diffuse skin thickening and fibrosis, and involves the heart, lungs, kidneys, digestive tract and other internal organs. autoimmune diseases, accompanied by damage to the microvascular system. Autoimmune reaction (hyperimmunoglobulinemia and multiple autoantibodies in serum), vascular disease (intima injury of small blood vessels and frequent Raynaud phenomenon in extremities and viscera) and collagen fiber proliferation in skin and visceral tissues are the leading causes. Systemic scleroderma produces three major...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/343A61P29/00A61P17/00A61P11/00
CPCA61K31/343
Inventor 王久存吴文育刘庆梅楚海燕宋萌萌马彦云袁晋鲁佳莹金力
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap